Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179630 · ClinicalTrials.gov registry record · Phase 1
Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
A Phase 1 study, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04179630 is a Phase 1 study that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT04179630, a Phase 1 study, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a single-center evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Renal Function.
Interventions
- BIOLOGICAL Aldafermin (NGM282)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-11-08 |
| Est. Completion | 2019-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04179630
The ClinicalTrials.gov registry entry for NCT04179630 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aldafermin (NGM282) is the first listed.
NCT04179630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04179630 about?
NCT04179630 is a clinical study titled "Study of Aldafermin (NGM282) in Participants With Impaired Renal Function". This is a single-center evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Renal Function.
What is the current status of trial NCT04179630?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-11-08. Estimated completion is 2019-12-14.
What interventions are being tested in trial NCT04179630?
The interventions under investigation include: Aldafermin (NGM282) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04179630?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.